Latest Aeterna Zentaris Inc. Stories
QUÉBEC CITY, Oct. 10, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that George R. Merriam, MD, Director of the Clinical Study Unit at the VA Puget Sound Health Care System, and Professor of Medicine at the University of Washington, Seattle and Tacoma, WA, will give an oral presentation on AEZS-130, Aeterna Zentaris' ghrelin agonist, at the 6(th) International Congress of the Growth Hormone Research (GRS) and Insulin-like...
Common shares will begin trading on a consolidated and split-adjusted basis on October 5, 2012 QUÉBEC CITY, Oct. 3, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the issued and outstanding common shares of the Company ("Common Shares") have been consolidated (the "Consolidation") on a six (6) to one (1) basis effective as of October 2, 2012. The purpose of the Consolidation is to enable the Company to attempt to...
Filing of Clinical Trial Application (CTA) in Prostate Cancer Expected in Q4 2012 QUEBEC CITY, Oct. 2, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that preclinical data on its oral prostate cancer vaccine candidate, AEZS-120, were presented over the weekend at the 32(nd) Congress of the Société Internationale d'Urologie, which is being held in Fukuoka, Japan. The presentation underlined the feasibility of an oral...
QUÉBEC CITY, QC, Sept. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it continues to expect to file a New Drug Application (NDA) early next year, for its oral ghrelin agonist, AEZS-130, as a diagnostic test for adult growth hormone deficiency (AGHD), after receiving notification from the United States Food and Drug Administration (FDA) that Fast Track designation had not been granted. Juergen Engel, PhD, President...
QUÉBEC CITY, Sept. 26, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and CFO, Dennis Turpin, CPA CA, will be presenting a corporate overview at BioContact on Wednesday, October 3, 2012, at 2 pm (Eastern), in the Grande-Allée Room of the Château Laurier Hotel in Québec City, Canada. About Aeterna Zentaris Aeterna Zentaris is an oncology and endocrinology drug development company...
QUEBEC CITY, Sept. 25, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the European Patent Office ("EPO") has granted a patent for the use of the ghrelin agonist, AEZS-130, related to methods and kits for use in relation to the diagnosis of growth hormone deficiency ("GHD") in a human or animal subject. Filed on February 19, 2007, the patent (EP #1 984 744 B1) titled, "Methods and Kits to Diagnose Growth Hormone...
QUEBEC CITY, Sept. 20, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a poster on its oral prostate cancer vaccine candidate, AEZS-120, will be on display at the upcoming 32(nd) Congress of the Société Internationale d'Urologie which will be held September 30 through October 4, 2012 at the Fukuoka International Congress Center in Fukuoka, Japan. The abstract #839 titled, "Pre-Clinical Proof of Concept and...
QUÉBEC CITY, Sept. 5, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its President and CEO, Juergen Engel, PhD, will be presenting a corporate overview at the Rodman & Renshaw 14(th) Annual Global Investment Conference on Tuesday, September 11, 2012, at 1:35 pm (Eastern), in the Starlight North Room of The Waldorf=Astoria Hotel in New York. A live webcast of this presentation will be available on Aeterna Zentaris'...
QUÉBEC CITY, Aug. 29, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will be presenting a corporate overview at the Stifel Nicolaus Healthcare Conference on Wednesday, September 5, 2012, at 11:30 am (Eastern), in the Winthrop Room of the Four Seasons Hotel in Boston. A live webcast of this presentation will be available on Aeterna Zentaris' website...
QUÉBEC CITY, Aug. 28, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that a first patient has been recruited for a Phase 2A trial with its ghrelin agonist, AEZS-130 in patients with cancer cachexia. The study is conducted under a Cooperative Research and Development Agreement (CRADA) between Aeterna Zentaris and the Michael E. DeBakey Veterans Affairs Medical Center which is funding the study. Cachexia, characterized by...
